Cantor Fitzgerald initiated coverage of Summit Therapeutics (SMMT) with an Overweight rating. The firm views shares as 67% undervalued, the analyst tells investors in a research note. Should ivonescimab continue to deliver superior efficacy relative to a PD-(L)1 class, it could become one of the most successful drugs ever, the firm argues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Summit Therapeutics names Robert LaCaze as Chief Commercial Officer
- Sunrun, HubSpot, Rocket, Summit, Cybin: Trending by Analysts
- PepsiCo downgraded, HubSpot upgraded: Wall Street’s top analyst calls
- Summit Therapeutics initiated with an Outperform at Evercore ISI